Clinicians weigh acalabrutinib vs zanubrutinib for relapsed CLL, focusing on adverse effects, trial data, and where ...
A new CIRI2-CLL model uses MRD and clinical data to better predict CLL survival after fixed-duration therapy, enabling ...
Shubham Pant, MD, MBBS, professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine at UT ...
Surbhi Sidana, MD, discusses the key aspects of iberdomide that make the CELMoD's FDA approval so significant for multiple ...
The FDA has approved rusfertide (Mimrylo) for adult patients with polycythemia vera (PV). 1 ...
Learn how oncologists spot burnout early and cut it with smarter workflows, PTO coverage, supportive leadership, and ...
The FDA has approved ropeginterferon alfa-2b-njft (Besremi) for adults with essential thrombocythemia (ET), marking the first ...
Singhi, MD, and participants discussed how the ROS1 G2032R resistance mutation is guiding second-line therapy selection in ROS1-positive advanced non–small cell lung cancer. After progression on a ...
Tumor hypoxia serves as a biologic marker of radioresistance, enabling maintenance of standard-intensity treatment when ...
Dual EGFR/MET blockade aims to counter MET overexpression–associated attenuation of EGFR TKI durability, potentially ...
August 2026 FDA oncology updates: iberdomide, zanidatamab and daraxonrasib win approvals as fast-track designations ...
The OS findings follow the recent FDA approval of zanidatamab with or without tislelizumab in HER2-positive gastroesophageal cancer. Zanidatamab-hrii (Ziihera) plus chemotherapy demonstrated a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results